Braeburn Pharmaceuticals was founded with a mission to provide innovative therapeutic solutions for opioid use disorder. The company focuses on addressing chronic brain diseases and offers comprehensive treatment options, including counseling and support services. Their flagship product, BRIXADI™, is designed to aid in the treatment of opioid addiction. Braeburn primarily serves the Pennsylvania market, aiming to improve patient outcomes and support recovery journeys.
Notable individuals affiliated with Braeburn include experts in the fields of addiction treatment and pharmaceutical development. The company has garnered significant investment to advance its research and development pipeline. Key achievements include the successful launch of BRIXADI™ and contributions to numerous publications and conference abstracts. Braeburn's impact is evident in its commitment to patient care and its role in combating the opioid crisis through effective therapeutic interventions.
